Upgrade to SI Premium - Free Trial

Rite Aid (RAD)

0.65 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- M&A (12/31/16 *Est)

Latest Headlines

Form 6-K Radiopharm Theranostics For: Aug 28 August 28, 2026 8:00 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Aug 27 August 27, 2026 8:00 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Aug 26 August 26, 2026 8:00 AM - SEC Filing Radiopharm doses first patient in second RV-01 trial cohort August 26, 2026 7:00 AM - StreetInsider Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors August 26, 2026 7:00 AM - Globe NewsWire Form 6-K Radiopharm Theranostics For: Aug 20 August 20, 2026 8:00 AM - SEC Filing Radiopharm trial advances to higher dose in HER2+ cancer study August 20, 2026 7:01 AM - StreetInsider Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial August 20, 2026 7:00 AM - Globe NewsWire Form 6-K Radiopharm Theranostics For: Aug 17 August 17, 2026 8:00 AM - SEC Filing Radiopharm sets FDA meeting for RAD101 brain metastases trial design August 17, 2026 7:30 AM - StreetInsider Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases August 17, 2026 7:30 AM - Globe NewsWire Form 6-K Radiopharm Theranostics For: Aug 13 August 13, 2026 8:00 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Jul 24 August 3, 2026 8:49 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Aug 03 August 3, 2026 8:00 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Jul 31 July 31, 2026 8:00 AM - SEC Filing Radiopharm Theranostics Reports Business Update July 31, 2026 7:00 AM - Globe NewsWire Form 6-K Radiopharm Theranostics For: Jul 28 July 28, 2026 11:59 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Jul 28 July 28, 2026 8:00 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Jul 27 July 27, 2026 6:06 AM - SEC Filing Form 424B5 Radiopharm Theranostics July 27, 2026 6:03 AM - SEC Filing Radiopharm raises up to $13M via US and Australian offerings July 24, 2026 7:15 AM - StreetInsider Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan July 24, 2026 7:15 AM - Globe NewsWire Form 6-K Radiopharm Theranostics For: Jul 24 July 24, 2026 7:00 AM - SEC Filing Form 424B5 Radiopharm Theranostics July 23, 2026 9:09 AM - SEC Filing Radiopharm reports partial response in RAD204 cancer drug trial July 22, 2026 7:05 AM - StreetInsider Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy July 22, 2026 7:05 AM - Globe NewsWire Radiopharm RAD101 meets Phase 2b endpoint for brain metastases July 22, 2026 7:00 AM - StreetInsider Form 6-K Radiopharm Theranostics For: Jul 22 July 22, 2026 7:00 AM - SEC Filing Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases July 22, 2026 7:00 AM - Globe NewsWire Form 6-K Radiopharm Theranostics For: Jul 03 July 6, 2026 7:00 AM - SEC Filing Form 6-K Radiopharm Theranostics For: Jun 30 June 30, 2026 9:11 AM - SEC Filing Full Article List